



Atty Dkt No. 029996-0278721  
Pat. App. Ser. No. 09/804,409

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Kieffer et al.

Group Art Unit: 1632

Appln. No.: 09/804,409

Examiner: P. Para, Jr.

Filed: March 12, 2001

Title:

COMPOSITIONS AND METHODS FOR  
REGULATED PROTEIN EXPRESSION IN  
GUT

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed cited references in this statement.

This IDS is being filed with a request for continued examination under Rule 114, and hence this IDS must be considered per Rule 97(b)(4).

**Certificate of Mailing Under 37 C.F.R. §1.10**

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being mailed via "Express Mail Post Office to Addressee" service of the United States Postal Service (Express Mail Label No. EL 988001674 US) on the date shown below in an envelope addressed to the Commissioner of Patent & Trademarks, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

By:   
Sachiko Y. Snedden

Date: June 16, 2004

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be construed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be construed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.


Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Respectfully submitted,

Pillsbury Winthrop LLP

Date: June 16, 2004

By

  
Robert M. Bedgood, Ph.D.  
Reg. No. 43,488

Tel. No. (858) 509-4065  
Fax No. (858) 509-4010

11682 El Camino Real  
Suite 200  
San Diego, CA 92130-2092  
(619) 234-5000

**FORM PTO-1449 (modified)**  
**To: U.S. Department of Commerce**  
**(PW FORM PAT-1449).**  
**Patent and Trademark Office**

Atty.	C-M#	Client Ref.
Dkt. No.		
	029996-0278721	

Applicant: Kieffer, et al.

Appln. No.: 09/804,409

Filing Date: March 12, 20

Filing Date: March 12, 2001

Examiner: P. Paras, Jr. Art Unit: 1632

Date: June 16, 2004

Page

1 | o

2

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

**Examiner**

Date Considered:

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.	C-	Client Ref.
			029996-0278721	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: Kieffer, et al.		
		Appln. No.: 09/804,409		
		Filing Date: March 12, 2001		
Date: June 16, 2004		Page <b>2</b> of <b>2</b>	Examiner: P. Paras, Jr.	Art Unit: 1632

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)		English Abstract		Translation Readily Available	
Initials*		Enclosed	No	Enclosed	No
	JR Lee et al.; Glucagon Gene 5'-Flanking Sequences Direct Expression of Simian Virus 40 large T Antigen to the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice; J. Biol. Chem., vol. 267, no. 15; May 1992; pp. 10705-10708				
	KR Gajic et al.; Multiple <i>cis</i> -Acting Domains Mediate Basal and Adenosine 3',5'-Monophosphate-Dependent Glucagon Gene Transcription in a Mouse Neuroendocrine Cell Line; Endocrinology, vol. 132, no. 3; 1993; pp. 1055-1062				
	LR Henning; Gene transfer into the intestinal epithelium; Advanced Drug Review, vol. 17; 1995; pp. 341-347				
	MR Kolodka et al.; Gene Therapy for Diabetes Mellitus in Rats by Hepatic Expression of Insulin; Proc. Natl. Acad. Sci. USA, vol. 92; April 1995; pp. 3293-3297				
	NR Efrat et al.; Glucagon Gene Regulatory Region Directs Oncoprotein Expression to Neurons and Pancreatic $\alpha$ Cells; Neuron, vol. 1; September 1998; pp. 605-613				
	OR Boylan et al.; Cell-specific Expression of the Glucose-dependent Insulinotropic Polypeptide Gene in a Mouse Neuroendocrine Tumor Cell Line; The Journal of Biological Chemistry, vol. 272, no. 28; July 1997; pp. 17438-17443				
	PR Croyle et al.; In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine; Gene Therapy, vol. 5; 1998; pp. 645-654				
	QR Yeung et al.; Glucose-dependent insulinotropic polypeptide gene expression in the stomach: revealed by a transgenic mouse study, in situ hybridization and immunohistochemical staining; Molecular and Cellular Endocrinology, vol. 154; 1999; pp. 161-170				
	RR Rutter et al.; Regulation of Mammalian Gene Expression by Glucose; News Physiol. Sci., vol. 15; June 2000; pp. 149-154.				
	SR During et al.; Peroral gene therapy of lactose intolerance using an adeno-associated virus vector; Nature Medicine, vol. 4, no. 10; October 1998; pp. 1131-1135				
	TR During et al.; An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy; Science; vol. 287; February 2000; pp. 1453-1460				
	UR Morsy et al.; Leptin gene therapy and daily protein administration: a comparative study in the ob/ob mouse; Gene Therapy, vol. 5; 1998; pp. 8-18				

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	